WO2007074868A1 - 新規なアリールアミジン誘導体およびその塩ならびにそれらを含有する抗真菌剤 - Google Patents
新規なアリールアミジン誘導体およびその塩ならびにそれらを含有する抗真菌剤 Download PDFInfo
- Publication number
- WO2007074868A1 WO2007074868A1 PCT/JP2006/326061 JP2006326061W WO2007074868A1 WO 2007074868 A1 WO2007074868 A1 WO 2007074868A1 JP 2006326061 W JP2006326061 W JP 2006326061W WO 2007074868 A1 WO2007074868 A1 WO 2007074868A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- reaction
- formula
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Definitions
- Novel arylamidine derivatives and salts thereof, and antifungal agents containing them Novel arylamidine derivatives and salts thereof, and antifungal agents containing them
- the present invention relates to a novel arylamidine derivative having antifungal activity, a salt thereof, and an antifungal agent containing them as an active ingredient.
- amphotericin B has a very strong bactericidal action, but there are side effects such as nephrotoxicity, which limits its clinical use. Because flucytosine has problems such as resistance, it is rarely used alone. Micafungin is weakly active against the genus Talyptococcus.
- Non-Patent Document 2 All other drugs are collectively referred to as azole antifungal agents, and the fungicidal action against fungi tends to be generally inferior to that of amphotericin B, but is currently the most frequently used due to the balance between efficacy and safety.
- Non-patent Document 3 The problem of resistance has a serious impact on the management of patients with deeply growing mycosis.
- Patent Documents 1 and 2 arylamidine derivatives having antifungal activity are known.
- Patent Document 1 International Publication No. 03Z074476
- Patent Document 2 International Publication No. 2006Z003881
- Non-Patent Document 1 Clinical and Microorganism, Vol.17, pp.265-266, 1990
- Non-Patent Document 2 Clinical and Microorganisms, Vol. 21, pp. 277-283, 1994
- Non-Patent Document 3 Clinical and Microorganisms, 28th, 51-58, 2001
- An antifungal agent having a different mechanism of action from existing drugs, effective against azole drug-resistant fungi, and having few side effects and excellent in oral absorption is strongly desired.
- R 1 and R 2 are the same or different C alkyl groups which may be substituted.
- the present invention has been completed by finding that it has excellent oral absorption, is effective against azole drug-resistant fungi, and has few side effects.
- the compound of the present invention has a strong activity against fungi including azole drug-resistant fungi, is excellent in oral absorption, exhibits high safety with little interaction with other agents, and is used as an antifungal agent. Useful.
- a halogen atom is a fluorine atom, a chlorine atom, a bromine atom and an iodine atom
- a lower alkyl group is, for example, methyl, ethyl, propyl, isopropyl, butyl, sec butyl Linear or branched C alkyl groups such as, isobutyl, tert butyl, pentyl and isopentyl;
- 1-6 3-4 groups include propyl, isopropyl, butyl, sec butyl, isobutyl and tert butyl groups; aralkyl groups include, for example, benzyl, diphenylmethyl, trityl, phenethyl and naphthylmethyl.
- alkyl group; an aralkyloxyalkyl group is, for example, benzyloxyme
- Al C alkyloxy C alkyl groups such as til and phenethyloxymethyl
- the alkanesulfol group refers to, for example, a calkanesulfol group such as methanesulfol, ethanesulfol, and propansulfol;
- a group such as benzenesulfol, toluenesulfol and naphthalenesulfol
- an alkanesulfoloxy group is a c-alkanesulfoloxy group such as methanesulfoloxy and ethanesulfoloxy
- Xoxy groups include, for example, groups such as benzenesulfo-loxy and toluenesulfo-loxy;
- the acyl group is, for example, a linear or branched C alkanoyl group such as formyl group, acetyl, propiol, and isovaleryl, or an al Cyl group such as benzyl carboyl.
- Alkylcarbol groups such as benzoyl and naphthoyl, nicotine
- Heterocyclic carbocyclic groups such as thiol, tenol, pyrrolidino carboyl and furoyl, and carboxy C alkyl such as 3 carboxypropanol and 4 carboxybutanol.
- C alkylcarbonyl groups 3- (methoxycarbol) propanoyl and 4 (methoxycarbol) butanol, etc.
- C alkyloxycarbons C alkylcarbol groups , Succinyl group, glutaryl group, maleoyl group, phthaloyl group and amino acids (for example, glycine, alanine, norin, leucine, isoleucine, serine, threonine, cysteine, methionine, aspartic acid, glutamic acid, asparagine, Such as glutamine, arginine, lysine, histidine, hydroxylysine, phenylalanine, tyrosine, tryptophan, proline, and hydroxyproline)).
- amino acids for example, glycine, alanine, norin, leucine, isoleucine, serine, threonine, cysteine, methionine, aspartic acid, glutamic acid, as
- An alkyloxycarbol group is, for example, methoxycarbol, ethoxycarbon, 1,1-dimethylpropoxycarbonyl, isopropoxy Carbonyl, 2-ethylyloxyl
- a linear or branched C alkyloxycarbonyl group such as bonyl, tert-butoxycarbonyl and tert-pentyloxypol;
- Alkyloxycarbonyl groups include, for example, alkyl C alkyloxy groups such as benzyloxycarbol and phenoxycarboxyl groups;
- an oxycarbonyl group refers to a group such as a phenylcarbocycle
- an oxygen-containing bicyclic group refers to a group such as tetrahydrofuryl and tetrahydrobilanyl
- the substituted silyl group is a group such as trimethylsilyl, triethylsilyl and tributylsilyl.
- Each of the above groups may be further substituted with one or more groups selected from a halogen atom, a hydroxyl group, a carboxyl group and a lower alkyl group.
- the amino protecting group includes all groups that can be used as protecting groups for ordinary amino groups.
- an acyl group an alkyloxycarbonyl group, an aralkyloxycarbonyl group, an aryloxy group.
- Examples thereof include a carbonyl group, an aralkyl group, an alkoxyalkyl group, an alkyloxyalkyl group, an alkanesulfol group, an arylsulfol group, and a substituted silyl group.
- the hydroxyl protecting group includes all groups that can be used as protecting groups for ordinary hydroxyl groups, and examples thereof include an acyl group, an alkyloxycarbonyl group, an aralkyloxycarbonyl group, and a heterocyclic oxycarbon group.
- Examples of the leaving group include a halogen atom, an alkanesulfonyloxy group, and an arylsulfo-oxy group.
- Salts of the compound of the general formula [1] include, for example, salts with mineral acids such as hydrochloric acid, hydrobromic acid, phosphoric acid and sulfuric acid; formic acid, trichlorodiacetic acid, L-tartaric acid, maleic acid, fumaric acid Salts with acids and organic carboxylic acids such as trifluoroacetic acid; and salts with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, ⁇ -toluenesulfonic acid, mesitylenesulfonic acid and naphthalenesulfonic acid.
- mineral acids such as hydrochloric acid, hydrobromic acid, phosphoric acid and sulfuric acid
- salts with sulfonic acids such as methanesulfonic acid,
- Preferable salts of the compound of the general formula [1] include pharmacologically acceptable salts.
- Examples of the substituent of the optionally substituted C alkyl group of R 1 and R 2 include a halogen atom.
- preferable compounds include the following compounds.
- R 1 is a C alkyl group
- R 1 is a C alkyl group
- a compound which is a butyl group which is more preferably a compound which is a ru group.
- R 2 is a C alkyl group
- R 2 is a C alkyl group
- a compound which is a butyl group which is more preferably a compound which is a ru group.
- the compound of the present invention is produced by a combination of methods known per se.
- the compound of the present invention can be produced by the following production method.
- the compound of the general formula [4] can be produced by reacting the compound of the formula [2] with the compound of the general formula [3] in the presence of an acid.
- the solvent used in this reaction is not particularly limited as long as it does not adversely affect the reaction, and examples thereof include alcohols such as methanol, ethanol, 2-propanol and 2-methyl-2-propanol; N , N-dimethylformamide, N, N-dimethylacetamide and amides such as 1-methyl-2-pyrrolidone; Halogenated hydrocarbons such as methylene chloride, chloroform and dichloroethane; benzene, toluene and xylene Aromatic hydrocarbons; ethers such as dioxane, tetrahydrofuran, azole, diethyleneglycolinoresmethinoleatenore, diethyleneglycololegetinolethenole and ethylene glycol monomethyl ether; sulfoxides such as dimethyl sulfoxide ;acetone Ketones such as pre-2-butanone; ⁇ Echiru and E ester compounds and carboxylic acids such as acetic acid, such as the like
- Examples of the acid used in this reaction include hydrogen chloride, hydrogen bromide, perchloric acid, p-toluenesulfonic acid, methanesulfonic acid, and the like. It may be 1 to 200 times mol, preferably 5 to 100 times mol, of the compound.
- the compound of the general formula [3] is preferably used as a solvent if it is used in an amount of 2 to 1000 moles compared to the compound of the formula [2].
- This reaction may be carried out at 30 to 150 ° C, preferably 10 to 50 ° C for 30 minutes to 24 hours.
- the compound of the formula [5] can be produced by reacting the compound of the general formula [4] with ammonia or an ammonium salt.
- the solvent used in this reaction is not particularly limited as long as it does not adversely influence the reaction.
- alcohols such as methanol, ethanol, 2-propanol and 2-methyl-2-propanol
- N N Amides such as dimethylformamide, N, N dimethylacetamide and 1-methyl-2-pyrrolidone
- Halogenated hydrocarbons such as methylene chloride, chloroform and dichloroethane
- Aromatic carbonization such as benzene, toluene and xylene Hydrogens
- ethers such as dioxane, tetrahydrofuran, azole, diethylene glycol dimethyl ether, diethylene glycol jetyl ether and ethylene glycol monomethyl ether
- -tolyls such as acetonitrile
- sulfoxides such as dimethyl sulfoxide
- Examples include heteroaromatics such as pyridine and water, and these may be used as a mixture.
- ammonium salt examples include ammonium chloride, ammonium bromide and ammonium acetate, and the amount of ammonia or ammonium salt used is generally It may be 3 to 100 times mol, preferably 3 to 10 times mol, of the compound of the formula [4]. This reaction may be carried out at 0 to 150 ° C, preferably 20 to 120 ° C for 1 minute to 24 hours.
- the compound of the general formula [1] can be produced by subjecting the compound of the formula [5] to a reactive derivative and an alkoxy carbo-Roi reaction in the presence or absence of a base.
- the solvent used in this reaction is not particularly limited as long as it does not adversely influence the reaction.
- amides such as N, N dimethylformamide, N, N dimethylacetamide and 1-methyl-2-pyrrolidone are used.
- Halogenated hydrocarbons such as methylene chloride, chloroform, and dichloroethane; benzene, toluene, xylene, etc.
- Aromatic hydrocarbons such as dioxane, tetrahydrofuran, azole, diethylene glycol dimethyl ether, diethylene glycol jetyl ether and ethylene glycol monomethyl ether; -tolyls such as acetonitrile; sulfoxides such as dimethyl sulfoxide; Examples include ketones such as acetone, methyl isobutyl ketone and 2-butanone; esters such as ethyl acetate; carboxylic acids such as acetic acid; heteroaromatics such as pyridine; and water. You can do it.
- Bases optionally used in this reaction include, for example, metal alkoxides such as sodium methoxide, sodium methoxide, potassium tert butoxide and sodium tert butoxide; sodium hydroxide, potassium hydroxide, carbonate, Inorganic salts such as sodium hydrogen, sodium carbonate, potassium carbonate, sodium hydride and potassium hydride, and triethylamine, N, N diisopropylethylamine, 1, 8 diazabicyclo [5. 4. 0] unde- (DBU) and organic bases such as pyridine.
- metal alkoxides such as sodium methoxide, sodium methoxide, potassium tert butoxide and sodium tert butoxide
- sodium hydroxide potassium hydroxide
- carbonate Inorganic salts such as sodium hydrogen, sodium carbonate, potassium carbonate, sodium hydride and potassium hydride
- Inorganic salts such as sodium hydrogen, sodium carbonate, potassium carbonate, sodium hydride and potassium hydride
- the amount of the reactive derivative and base used may be 2 to 100 times mol, preferably 2 to 10 times mol, of the compound of the formula [5].
- This reaction may be carried out at 20-100 ° C, preferably 20-80 ° C for 1 minute-24 hours.
- R 4 represents an optionally substituted acyl, lower alkyl or aralkyl group; R 1 and R 2 have the same meaning as described above.”
- the compound of the formula [6] can be produced from the compound of the formula [2]. Subsequently, the compound of the general formula [7] can be produced by alkylating or acylating the compound of the formula [6]. Furthermore, the compound of the formula [5] can be produced by reducing the compound of the formula [6]. Further, the compound of the formula [5] can be produced by reducing the compound of the general formula [7]. These reactions are described in Tetrahedron, 51st, 1204 712068, 1995; Synthetic Communication, 26th, 4351-4367, 1996; Synthesis. ), Pp. 16, pp. 2467-2469, 2003; Heterocycles, pp. 60, pp.
- the compound of the general formula [1] can be produced by alkoxylating the compound of the formula [5].
- the compound of the formula [6] can be produced by reacting the compound of the formula [2] with hydroxylamine or a salt thereof in the presence or absence of a base.
- the solvent used in this reaction is not particularly limited as long as it does not adversely influence the reaction.
- alcohols such as methanol, ethanol, 2-propanol and 2-methyl-2-propanol
- N, N — Amides such as dimethylformamide, N, N-dimethylacetamide and 1-methyl-2-pyrrolidone
- Halogenated hydrocarbons such as methylene chloride, cycloform and dichloroethane
- Fragrances such as benzene, toluene and xylene Group hydrocarbons
- ethers such as dioxane, tetrahydrofuran, azole, diethylene glycol dimethyl ether, diethylene glycol jetyl ether and ethylene glycol monomethyl ether
- sulfoxides such as dimethyl sulfoxide
- acetone and 2-butano Ketones such as
- hetero aromatics and water such as pyridine and the like, may be used which are mixed.
- Bases optionally used in this reaction include, for example, metal alkoxides such as sodium methoxide, sodium methoxide, potassium tert-butoxide and sodium tert-butoxide; sodium hydroxide, sodium hydroxide, potassium hydroxide Inorganic salts such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate, sodium hydride and potassium hydride, and organic bases such as tritylamine and pyridine.
- metal alkoxides such as sodium methoxide, sodium methoxide, potassium tert-butoxide and sodium tert-butoxide
- sodium hydroxide sodium hydroxide
- potassium hydroxide Inorganic salts such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate, sodium hydride and potassium hydride
- organic bases such as tritylamine and pyridine.
- the amount of the base used may be 2 to 100 times mol, preferably 2 to 20 times mol, of the compound of formula [2].
- Examples of the salt of hydroxylamine include hydrochloride and sulfate.
- the amount of hydroxylamine or a salt thereof used may be 2 to 100 times mol, preferably 2 to 20 times mol, of the compound of formula [2].
- This reaction may be carried out at 0 to 150 ° C, preferably 50 to 150 ° C for 1 minute to 24 hours.
- the compound of the general formula [7] can be produced by reacting the compound of the formula [6] with a reactive derivative or an alkylating agent in the presence or absence of a base.
- any solvent that does not adversely affect the reaction may be used.
- examples include, but are not limited to, amides such as N, N dimethylformamide, N, N dimethylacetamide and 1-methyl-2-pyrrolidone; halogenated hydrocarbons such as methylene chloride, chloroformate and dichloroethane; benzene, toluene And aromatic hydrocarbons such as xylene; ethers such as dioxane, tetrahydrofuran, ether, diethylene glycol dimethyl ether, diethylene glycol jetyl ether and ethylene glycol monomethyl ether; -tolyls such as acetonitrile; dimethyl sulfoxide, etc.
- Examples include sulfoxides; ketones such as acetone and 2-butanone; esters such as ethyl acetate; carboxylic acids such as acetic acid; heteroaromatics such as pyridine and water. It may also be used.
- a reactive derivative may be generated in the system using a coupling reagent!
- Coupling reagents include, for example, carbodiimides such as N, N, monodicyclohexylcarbodiimide and Nethyl N ′-(3-dimethylaminopropyl) carbodiimide; carbo-diimidazole and other carbodiimides.
- Acid azides such as diphenyl phosphoryl azide; acid cyanides such as jetyl phosphoryl cyanide; 2-ethoxy 1 ethoxycarbonyl 1, 2 dihydroquinoline; O benzotriazole 1-yl 1, 1, 3, 3—Tetramethyluronium hexafluorophosphate; and O— (7-azabenzotriazole 1-yl) -1, 1, 3, 3—Tetramethylol-um-hexa Examples include fluorophosphate.
- alkylating agent examples include halogens such as methyl iodide and iodoacetyl.
- Alkyl halides examples include halogens such as methyl iodide and iodoacetyl.
- Alkyl halides examples include halogens such as methyl iodide and iodoacetyl.
- Alkyl halides examples include halogens such as methyl iodide and iodoacetyl.
- aralkyl halides such as benzyl chloride and benzyl bromide
- sulfate esters such as dimethyl sulfate.
- Bases optionally used in this reaction include, for example, metal alkoxides such as sodium methoxide, sodium methoxide, potassium tert butoxide and sodium tert butoxide; sodium hydroxide, potassium hydroxide, carbonate, Examples include inorganic salts such as sodium hydride, sodium carbonate, potassium carbonate, sodium hydride and potassium hydride, and organic bases such as tritylamine and pyridine.
- metal alkoxides such as sodium methoxide, sodium methoxide, potassium tert butoxide and sodium tert butoxide
- sodium hydroxide potassium hydroxide
- carbonate examples include inorganic salts such as sodium hydride, sodium carbonate, potassium carbonate, sodium hydride and potassium hydride, and organic bases such as tritylamine and pyridine.
- the amount of the reactive derivative, alkylating agent and base used may be 2 to 100 times mol, preferably 2 to 10 times mol, of the compound of the formula [6].
- This reaction may be carried out at 20 to 100 ° C, preferably 0 to 50 ° C for 1 minute to 24 hours.
- the compound of the formula [5] can be produced by subjecting the compound of the formula [6] to a reduction reaction.
- the compound of the formula [5] can be produced by subjecting the compound of the general formula [7] to a reduction reaction.
- Examples of the reduction reaction used here include a catalytic hydrogenation reaction using a metal catalyst and a reduction using a metal and an acid such as zinc acetate.
- the solvent used is not particularly limited as long as it does not adversely influence the reaction.
- Alcohols such as methanol, ethanol, 2-propanol and 2-methyl-2-propanol; amides such as N, N dimethylformamide, N, N dimethylacetamide and 1-methyl-2-pyrrolidone; methylene chloride, chloride Halogenated hydrocarbons such as oral form and dichloroethane; Aromatic hydrocarbons such as benzene, toluene and xylene; Dioxane, Tetrahydrofuran, Carsol, Diethylene glycol dimethyl ether, Diethylene glycol jetyl ether and Ethylene glycol monomethyl ether Ethers such as; -Tolyls such as ril; ketones such as acetone and 2-butanone; esters such as ethyl acetate; carboxy
- Examples of the metal catalyst include palladium catalysts such as palladium-carbon, palladium oxide, palladium hydroxide and palladium black; nickel catalysts such as Raney nickel, and acid-platinum.
- the amount of the compound of the formula [6] or the compound of the general formula [7] may be 0.001 to 1 times (wZw), preferably 0.01 to 0.5 times (wZw).
- reducing agents other than hydrogen examples include formic acid; formate salts such as sodium formate, ammonium formate, and triethylammonium formate; cyclohexene, and cyclohexadiene.
- the amount may be 2 to 100 times mol, preferably 2 to 10 times mol, of the compound of the formula [6] or the compound of the general formula [7].
- the hydrogen pressure may be normal pressure to 30 atm, preferably 2 to 10 atm.
- the hydrogen pressure may be normal pressure
- This reaction may be carried out at 0 to 200 ° C, preferably 0 to 100 ° C for 1 minute to 24 hours.
- the compound of the general formula [1] can be produced by subjecting the compound of the formula [5] to a reactive derivative and an alkoxy carbo-Roi reaction in the presence or absence of a base. This reaction should be carried out according to production method 13.
- R 5 may be substituted.
- R 2 and R 3 have the same meaning as described above.
- the compound of the general formula [9] can be produced from the compound of the general formula [4]. By reducing the compound of the general formula [9], the compound of the formula [5] can be produced. Next, the compound of the general formula [1] can be produced by subjecting the compound of the formula [5] to an alkoxycarboxylation.
- the compound of the general formula [9] can be produced by reacting the compound of the general formula [4] with the compound of the general formula [8] or a salt thereof.
- Examples of the compound of the general formula [8] include O-methylhydroxylamine and O-benzylhydroxylamine.
- Examples of the salt of the compound of the general formula [8] include hydrochloride and sulfate.
- This reaction may be carried out according to production method 1-2.
- the compound of the formula [5] can be produced by reducing the compound of the general formula [9]. This reaction may be carried out according to production method 2-3. [0046] (3-3)
- the compound of the general formula [1] can be produced by subjecting the compound of the formula [5] to a reactive derivative and an alkoxy carbo-Roi reaction in the presence or absence of a base. This reaction should be carried out according to production method 13.
- Solvents, hydrates and crystals of various shapes can be used for the compounds in the above-described production methods.
- the compound of the formula [2] is produced by combining methods known per se, and can be produced, for example, by the production method shown below.
- tert butyl 4 (3-hydroxypropyl) 1-piperidinecarboxylate It can also be synthesized by combining methods.
- the compound of the formula [12] can be produced by reacting the compound of the general formula [10] with the compound of the formula [11] in the presence or absence of a base and then deprotecting it.
- the solvent used in this reaction is not particularly limited as long as it does not adversely influence the reaction.
- alcohols such as methanol, ethanol, 2-propanol and 2-methyl-2-propanol
- N, N — Amides such as dimethylformamide, N, N-dimethylacetamide and 1-methyl-2-pyrrolidone
- Halogenated hydrocarbons such as methylene chloride, chloroform and dichloroethane
- Fragrances such as benzene, toluene and xylene Aromatic hydrocarbons
- ethers such as dioxane, tetrahydrofuran, amine, diethylene glycol dimethyl ether, diethylene glycol jetyl ether and ethylene glycol monomethyl ether
- -tolyls such as acetonitrile
- sulfoxide such as dimethyl sulfoxide Ketones such as acetone and 2-butanone
- earth esters such as acetate Echiru; etc.
- Bases optionally used in this reaction include, for example, metal alkoxides such as sodium methoxide, sodium methoxide, potassium tert-butoxide and sodium tert-butoxide; sodium hydroxide, sodium hydroxide, Examples thereof include inorganic bases such as sodium bicarbonate, sodium carbonate, potassium carbonate, sodium hydride and potassium hydride, and organic bases such as triethylamine, N, N-diisopropylethylamine and pyridine.
- metal alkoxides such as sodium methoxide, sodium methoxide, potassium tert-butoxide and sodium tert-butoxide
- sodium hydroxide sodium hydroxide
- examples thereof include inorganic bases such as sodium bicarbonate, sodium carbonate, potassium carbonate, sodium hydride and potassium hydride, and organic bases such as triethylamine, N, N-diisopropylethylamine and pyridine.
- the amount of the base used may be 1 to 10 times mol, preferably 1 to 3 times mono to the compound of the general formula [10].
- the amount of the compound of the formula [11] used in this reaction is 1 with respect to the compound of the general formula [10].
- This reaction may be carried out at 0 to 200 ° C, preferably 0 to 150 ° C for 1 minute to 24 hours.
- the removal of the amino protecting group represented by R 6 can be carried out, for example, by protecting groups in organic synthesis brother 3fe, 494: If you follow the method described on page 653, 1999, etc. or a method similar to it.
- the compound of the formula [2] can be produced by reacting the compound of the formula [12] with the compound of the general formula [13]. This reaction may be carried out according to production method A-1.
- R 7 represents a hydrogen atom or a hydroxyl protecting group
- the compound of the formula [15] can be produced by reacting the compound of the general formula [13] with the compound of the general formula [14] and then deprotecting as necessary. This reaction may be performed according to production method A-1.
- the compound of the general formula [16] can be produced by converting the hydroxyl group of the compound of the formula [15] into a leaving group.
- the compound of formula [15] can be reacted in the presence or absence of a base, for example, an alkane sulfone such as methanesulfo-l-chloride. It can be reacted with arylsulfonyl chloride such as -l-chloride or p-toluenesulfonic acid chloride.
- a base for example, an alkane sulfone such as methanesulfo-l-chloride. It can be reacted with arylsulfonyl chloride such as -l-chloride or p-toluenesulfonic acid chloride.
- Bases optionally used in this reaction include, for example, metal alkoxides such as sodium methoxide, sodium metoxide, potassium tert butoxide and sodium tert butoxide; sodium hydroxide, potassium hydroxide, hydrogen carbonate Examples thereof include inorganic bases such as sodium, sodium carbonate, potassium carbonate, sodium hydride and potassium hydride, and organic bases such as triethylamine, N, N diisopropylethylamine and pyridine.
- metal alkoxides such as sodium methoxide, sodium metoxide, potassium tert butoxide and sodium tert butoxide
- sodium hydroxide potassium hydroxide
- hydrogen carbonate examples thereof include inorganic bases such as sodium, sodium carbonate, potassium carbonate, sodium hydride and potassium hydride, and organic bases such as triethylamine, N, N diisopropylethylamine and pyridine.
- the amount of the alkylsulfonyl chloride or arylsulfuryl chloride and the base used may be 1 to 10 times mol, preferably 1 to 3 times mol, of the compound of the formula [15].
- the leaving group is a halogen atom
- the compound of the formula [15] is reacted with, for example, chloro chloride, thionyl bromide, boron tribromide, carbon tetrabromide triphenylphosphine and the like. You can do it.
- the amount of these reagents to be used may be 1 to 10 times mol, preferably 1 to 3 times mono to the compound of the formula [15].
- the solvent used in this reaction is not particularly limited as long as it does not adversely influence the reaction.
- N, N dimethylformamide, N, N dimethylacetamide and 1-methyl-2-pyrrolidone Amides such as; Halogenated hydrocarbons such as methylene chloride, chloroform, and dichloroethane; Aromatic hydrocarbons such as benzene, toluene, and xylene; Dioxane, Tetrahydrofuran, Carsol, Diethylene glycol dimethyl ether, Diethylene glycol jetyl Ethers such as ether and ethylene glycol monomethyl ether; -tolyls such as acetonitrile; sulfoxides such as dimethyl sulfoxide; and heteroaromatics such as pyridine. These may be used as a mixture.
- the compound of the formula [2] can be produced by reacting the compound of the general formula [16] with the compound of the formula [11]. This reaction may be performed according to production method A-1.
- Examples of the compound of the general formula [17] include 3 chloro-1 propanol and 3-bromo-1 propanol.
- the compound of the formula [18] can be produced by reacting the compound of the formula [11] with a compound of the general formula [17]. This reaction may be performed according to production method A-1.
- the compound of the general formula [13] can be produced by converting the hydroxyl group of the compound of the formula [18] into a leaving group. This reaction may be performed according to production method B-2.
- formulation adjuvants such as excipients, carriers and diluents that are usually used in the formulation may be appropriately mixed according to conventional methods.
- Capsules, powders, syrups, granules, pills, suspensions, emulsions, solutions, powders, suppositories, eye drops, nasal drops, ear drops, patches, ointments, injections, etc. Can be administered orally or parenterally.
- the administration method, the dosage, and the number of administrations can be appropriately selected according to the age, weight and symptoms of the patient.
- oral administration or parenteral administration for example, injection, infusion, administration to the rectal site, etc.
- 0.01 to 1000 mg Zkg may be administered in several divided doses once a day.
- Test Example 1 Candida infection model test in mice (oral administration)
- Example Example 2 As test compounds, the compounds of Example Example Example 2, Example 3 and Example 4 were used.
- Candida albicans TIMM1623 on a Sabouraud dextrose agar plate (SDA) plate cultured overnight at 35 ° C was suspended in sterile physiological saline and diluted to prepare an inoculated bacterial solution.
- SDA Sabouraud dextrose agar plate
- mice In order to make male mice (4 weeks old, 5 mice per group) transiently susceptible to infection, cyclophosphamide 200 mg / kg and 100 mg / kg were administered intraperitoneally 4 days before infection.
- the prepared strain N. albicans TIMM1623 inoculated 0.2 mL was inoculated into the tail vein of mice to induce infection (approximately 3 ⁇ 10 4 CFU / mouse).
- the test compound was dissolved in O.lmol / L hydrochloric acid, diluted with sterilized water, and orally administered in terms of 3 mg / kg per mouse body weight. Treatment started 2 hours after infection and was performed once a day for 7 days.
- Example 1 The same amount of sterile physiological saline was administered to the test compound non-administered group. The number of surviving mice was observed and recorded for 14 days after infection. As a result, all mice died in the test compound non-administered group. On the other hand, in the compound administration groups of Example 1, Example 2, Example 3, and Example 4, 80% or more of the mice survived. Examples The compounds of Example 2, Example 3 and Example 4 showed excellent therapeutic effects.
- Example 3 The compound of Example 3 was used as a test compound.
- cyclophosphamide was intraperitoneally administered 200 mg / kg 4 days before infection and 100 mg / kg the day after infection.
- Candida albicans TIMM1623 cultured at 35 ° C in SDA was suspended in sterile physiological saline, adjusted to 1.5 ⁇ 10 5 cells / mL, and 0.2 mL was inoculated into the tail vein of mice to cause infection (about approx. 3 x 10 4 CFU / mouse).
- test compound was dissolved in a small amount of O.lmol / L hydrochloric acid and then diluted with sterile physiological saline (0.01 mg / mL) and subcutaneously administered at 10 mL / kg per mouse body weight (0.1 mg per body weight). /kg). The administration was performed once 2 hours after infection, once a day for 3 days from the next day, for a total of 4 times. The same amount of sterile physiological saline was administered to the test compound non-administered group. The number of surviving mice was observed and recorded for 21 days after infection.
- mice died in the test compound non-administered group.
- the compound administration group of Example 3 80% of the mice survived.
- the compound of Example 3 showed an excellent therapeutic effect.
- Example 3 As a test compound, the compound of Example 3 and Comparative Compound 1 were used.
- Aspergillus fomigatus IFM46895 spores were cultured on potato dextrose agar at 30 ° C for 1 week. Spores were collected, suspended in sterile physiological saline supplemented with 0.05% Tween 80, and diluted to prepare an inoculum solution.
- cyclophosphamide was intraperitoneally administered 200 mg / kg 4 days before infection and 100 mg / kg the day after infection.
- 0.2 mL of the inoculum was inoculated into the tail vein of mice to induce infection (about 1 X 10 5 CFU / mouse).
- the test compound was dissolved in a small amount of O.lmol / L hydrochloric acid and then dissolved in diluted distilled water (lmg / mL) and orally administered at 10 mL / kg per mouse body weight (10 mg / kg per body weight). Administration is infection 2
- the test was performed 7 times, once after the time and once a day for 6 days from the following day.
- mice The same amount of sterile physiological saline was administered to the test compound non-administered group. The number of surviving mice was observed and recorded for 21 days after infection. As a result, all mice died in the test compound non-administered group. In the Comparative Compound 1 administration group, 20% of mice survived. On the other hand, in the compound administration group of Example 3, 80% of mice survived.
- the compound of Example 3 showed an excellent therapeutic effect.
- Test Example 4 Aspergillus infection model test in mice (subcutaneous administration)
- Example 3 The compound of Example 3 was used as a test compound.
- cyclophosphamide was intraperitoneally administered 200 mg / kg 4 days before infection and 100 mg / kg the day after infection.
- 0.2 mL of the inoculum was inoculated into the tail vein of mice to induce infection (about 1 X 10 5 CFU / mouse).
- the test compound was dissolved in a small amount of O.lmol / L hydrochloric acid, then diluted with sterile physiological saline (0.03 mg / mL), and subcutaneously administered at 10 mL / kg of mouse body weight (0.3 mg / kg of body weight). kg).
- Administration was carried out once 2 hours after infection, once a day from the next day for 6 days, a total of 7 times.
- the same amount of sterile physiological saline was administered to the test compound non-administered group.
- the number of surviving mice was observed and recorded for 21 days after infection.
- mice died in the test compound non-administered group.
- 60% of mice survived.
- the compound of Example 3 showed an excellent therapeutic effect.
- Example 1 As test compounds, the compounds of Example 1 and Example 2 and Comparative Compound 1 were used.
- Vero cells were used to assess compound cytotoxicity. Each test compound was dissolved in dimethyl sulfoxide (DMSO) to prepare 10 mg / mL. Dilute with E'MEM with 10% FBS and add 96 Attached to the well plate (final concentration: g / mL). Suspend cells in E'MEM containing 10% FBS, inoculate 3000 cells / well (96 well plate), and incubate at 37 ° C for 3 days.
- DMSO dimethyl sulfoxide
- Vero cells Incubated in one.
- PMS methosulphate
- the compound of the present invention was much safer than Comparative Compound 1.
- a repeated intravenous dose toxicity test was conducted using male ICR mice (6 weeks old, 5 mice per group) using the compound of Example 3, Comparative Compound 2 and Comparative Compound 3. Carried out.
- An administration solution was prepared by adding 3 times molar amount of hydrochloric acid to each test compound and further adding sterile physiological saline.
- the compound of Example 3 and Comparative Compound 2 were each administered 25 mg / kg, and Comparative Compound 1 was administered 6.25 mg / kg into the tail vein once a day for 3 days.
- sterile physiological saline was administered to the control group.
- Each mouse was anesthetized with ether on the first day after the administration.
- Blood was collected from the abdominal vena cava using a syringe containing heparin solution (Novo'Heparin Injection 1000, Aventis Pharma Co., Ltd.) as a blood coagulation inhibitor, and centrifuged (3300 rpm, 4 ° C, 10 minutes, KUBOTA5900 Plasma was obtained by mold).
- heparin solution Novo'Heparin Injection 1000, Aventis Pharma Co., Ltd.
- ALT aspartate aminotransferase
- ALT alanine For aminotransferases
- Example 3 The compound of Example 3 was strong without any abnormality in AST and ALT. On the other hand, Comparative Compounds 2 and 3 showed an increase in AST and ALT indicating the onset of liver damage.
- Test Example 7 Mouse acute toxicity test (oral administration)
- the compound of Example 3 was prepared as a lOOmg / mL suspension with 0.1 mol / L hydrochloric acid.
- the test compound solution was orally administered to male mice (6 weeks old, 2 mice per group) at 10 mL / kg (1000 mg / kg per body weight) and observed until 2 days later.
- Test Example 8 Mouse acute toxicity test (intravenous administration)
- the compound of Example 3 was dissolved in a small amount of 0.1 mol / L hydrochloric acid and adjusted to 5 mg / mL with sterile physiological saline.
- the test compound solution was intravenously administered to male mice (4 weeks old, 2 mice per group) at 10 mL / kg (50 mg / kg per body weight) and observed until 2 days later.
- Test Example 9 Inhibitory action of liver drug metabolizing enzymes in humans
- the inhibitory activity of human liver drug metabolizing enzyme CYP2D6 of the compound of Example 3, Comparative Compound 1, Comparative Compound 2, and Comparative Compound 3 was compared.
- the substrate was 3- [2- (N, N-jetyl-1-N-methylammo- um) ethyl] -7-methoxy-1-methylcoumarin iodide.
- the reaction is carried out in phosphate buffer (100 mmol / L, pH 7.4).
- the final concentration of the reaction system is 20 nmol / L enzyme, 1.5 ⁇ mol / L substrate, nicotinamide adenine dinucleotide phosphate oxidized form ( NADP +) 1.55 mmol / L, glucose 6-phosphate 3.3 mmol / L, magnesium chloride 3.3 mmol / L, glucose 6-phosphate dehydrogenase (G6PDH) 0.4 Unit S / mL.
- the concentration of each compound in the reaction solution was a 3-fold dilution series, and the final concentration ranged from 72 to 0.0329 / z mol / L. Repeat these reactions at 37 ° C for 30 minutes. I adapted it.
- Keijin was used as a positive control.
- Example 3 did not inhibit human CYP2D6 at 72 mol / L. Comparative Compound 1 strongly inhibited human CYP2D6 with an IC of 0.68 ⁇ mol / L. Comparative compound 2 and comparison
- the inhibitory activity of the compound of Example 3 and Comparative Compound 1 on human liver drug-metabolizing enzyme CYP2C19 was compared.
- a microsome expressing human CYP2C19 in insect cells was used and dibenzylfluorescein was used as a substrate.
- the reaction is carried out in phosphate buffer (100 mmol / L, pH 7.4).
- the final concentration of the reaction system is 15 nmol / L enzyme, substrate 1.0 / z mol / L, nicotinamide adenine dinucleotide phosphate oxidized form ( NADP +) 1.55 mmol / L, dalcose 6-phosphate 3.3 mmol / L, magnesium chloride 3.3 mmol / L, glucose 6-phosphate dehydrogenase (G6PDH) 0.4 Unit S / mL.
- the concentration of each compound in the reaction solution was a 3-fold dilution series, and the final concentration ranged from 72 to 0.0329 / z mol / L. These reaction solutions were reacted at 37 ° C for 30 minutes.
- Example 3 did not inhibit human CYP2C19 at 72 mol / L.
- Comparative Compound 1 strongly inhibited human CYP2C19 with IC 4.36 ⁇ mol / L.
- the inhibitory activity of the compound of Example 3 and Comparative Compound 1 on human liver drug-metabolizing enzyme CYP3A4 was compared.
- a microsome expressing human CYP3A4 in insect cells was used, and dibenzylfluorescein was used as a substrate.
- the reaction is carried out in phosphate buffer (100 mmol / L, pH 7.4).
- the final concentration of the reaction system is enzyme 2.5 nmol / L, substrate 1.0 / z mol / L, nicotinamide adenine dinucleotide phosphate oxidized form (NADP +) 1.55 mmol / L, dalcose 6-phosphate 3.3 mmol / L, magnesium chloride 3.3 mmol / L, glucose 6-phosphate dehydrogenase (G6PDH) 0.4 Unit S / mL.
- the concentration of each compound in the reaction solution should be a 3-fold dilution series.
- the final concentration was a concentration range of 72 to 0.0329 / z mol / L.
- Comparative compound 1 strongly inhibited human CYP3A4 with an IC of 4.73 ⁇ mol / L.
- the compound of the present invention was superior in safety with less drug interaction with other agents than the comparative compound in which the inhibitory action of various liver drug metabolizing enzymes was weak.
- the mixing ratios in the eluent are all volume ratios, and B.W.silica gel and BW-127ZH (Fuji Silicon Chemical Co., Ltd.) were used as the carriers in column chromatography unless otherwise specified.
- Potassium tert-butoxide 9.42 g of N, N-dimethylformamide lOOmL suspension, under water cooling, 4-canophenol 10.0 g and 3-chloro 1-propanol 7.02 mL was added and stirred at 100 ° C for 1 hour. did. After cooling the reaction mixture to room temperature, 200 mL of water and 200 mL of ethyl acetate were added. The organic layer was separated, washed successively with 5% aqueous potassium carbonate solution and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was removed under reduced pressure.
- 3- (4 cyanophenoxy) propyl methanesulfonate 50.0 g of N, N dimethylformamide in 250 mL solution at room temperature 32.5 g potassium iodide, 32.9 g sodium bicarbonate and 3- (4-piveridyl) 1 propanol hydrochloride 37.0 g was added and stirred at 70 ° C for 7 hours. After the reaction mixture was cooled to room temperature, 250 mL of water and 150 mL of toluene were added, and the pH was adjusted to 1.0 with hydrochloric acid. The aqueous layer was separated, adjusted to ⁇ . ⁇ with a 20% sodium hydroxide aqueous solution, and stirred for 15 minutes at room temperature and 30 minutes under ice cooling.
- the obtained solid was dissolved in black mouth form, washed successively with 5% aqueous potassium carbonate solution and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure.
- ⁇ 3-—4- (3 -— ⁇ 4 [Amino (propoxycarbo-luimino) methyl] phenoxy ⁇ propyl) 1-piveridyl-propoxy ⁇ N, 1 (propoxycarbol) benzamidin (1.25 g) was obtained.
- Isobutyl 4-12 tropenyl carbonate 1.82 g of N, N dimethylformamide in 15 mL solution at room temperature 4— ⁇ 3— [4— (3— ⁇ 4— [Amino (imino) methyl] phenoxy ⁇ propyl) 1-piverige -Lu] propoxy ⁇ benzamidine 1.50 g was added and reacted at the same temperature for 17 hours. To the reaction mixture was added black mouthform and water. The organic layer was separated, washed successively with water, 5% aqueous potassium carbonate solution and saturated aqueous sodium chloride solution, and then dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure.
- the obtained residue was dissolved in black mouth form, washed successively with 5% aqueous potassium carbonate solution and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure to obtain a white solid.
- Example 1 500 mg of the compound obtained in Example 1, 350 mg of lactose, 250 mg of corn starch, and 400 mg of crystalline cellulose [Product name: Cerath PH101: Asahi Kasei Chemicals] were mixed and kneaded with 0.6 mL of 5% hydroxypropylcellulose aqueous solution and water. Combined. The obtained mixture was dried at 60 ° C. and then mixed with 100 mg of crospovidone [trade name: Kollidon CL: BASF], 10 mg of light anhydrous silicic acid lOO mg and 20 mg of magnesium stearate. 175 mg of the mixture was tableted as a round tablet with a diameter of 8 mm to obtain a tablet.
- crospovidone trade name: Kollidon CL: BASF
- Example 2 The compound obtained in Example 1 (500 mg), lactose (200 mg), and corn starch (530 mg) were mixed, and kneaded with 0.6% 5% hydroxypropylcellulose aqueous solution and water. After the resulting mixture was dried at 60 ° C, 70 mg of crospovidone [trade name: Kollidon CL: BASF], 180 mg of crystalline cellulose [trade name: Cerath PH302: Asahi Kasei Chemicals] and 20 mg of magnesium stearate were collected. Mixed. 150 mg of the mixture was filled into a No. 3 gelatin capsule to obtain a capsule.
- the compound of the present invention has strong activity against fungi including azole drug-resistant fungi, is excellent in oral absorption, exhibits high safety, and is useful as an antifungal agent.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007552006A JP5038155B2 (ja) | 2005-12-29 | 2006-12-27 | 新規なアリールアミジン誘導体およびその塩ならびにそれらを含有する抗真菌剤 |
NZ569317A NZ569317A (en) | 2005-12-29 | 2006-12-27 | Novel arylamidine derivative, salt thereof and antifungal agent containing those |
SI200630810T SI1967190T1 (sl) | 2005-12-29 | 2006-12-27 | Nov derivat arilamidina, njegova sol in le-te vsebujoäśe protigliviäśno sredstvo |
BRPI0620732-4A BRPI0620732A2 (pt) | 2005-12-29 | 2006-12-27 | composto, e, agente antifúngico |
US12/159,527 US8536343B2 (en) | 2005-12-29 | 2006-12-27 | Arylamidine derivative, salt thereof and antifungal agent containing those |
EP06843443A EP1967190B1 (en) | 2005-12-29 | 2006-12-27 | Novel arylamidine derivative, salt thereof and antifungal agent containing those |
CA2634846A CA2634846C (en) | 2005-12-29 | 2006-12-27 | Novel arylamidine derivative, salt thereof and antifungal agent containing those |
DK06843443.0T DK1967190T3 (da) | 2005-12-29 | 2006-12-27 | Nyt arylamidin-derivat, salt deraf og svampebekæmpelsesmiddel indeholdende dette |
AU2006330408A AU2006330408B2 (en) | 2005-12-29 | 2006-12-27 | Novel arylamidine derivative, salt thereof and antifungal agent containing those |
KR1020087018282A KR101359363B1 (ko) | 2005-12-29 | 2006-12-27 | 신규의 아릴아미딘 유도체 및 그 염과 그들을 함유하는항진균제 |
PL06843443T PL1967190T3 (pl) | 2005-12-29 | 2006-12-27 | Nowa pochodna aryloamidyny, jej sól i środek przeciwgrzybiczy zawierający te substancje |
DE602006016010T DE602006016010D1 (de) | 2005-12-29 | 2006-12-27 | Neues arylamid-derivat, salz davon und diese enthaltendes antimykotisches mittel |
CN2006800497554A CN101351204B (zh) | 2005-12-29 | 2006-12-27 | 芳脒衍生物及其盐、以及含有它们的抗真菌药 |
NO20082698A NO20082698L (no) | 2005-12-29 | 2008-06-12 | Nye derivater, deres salter og antisoppmidler inneholdende disse |
IL192380A IL192380A0 (en) | 2005-12-29 | 2008-06-22 | Novel arylamidine derivative, salt thereof and antifungal agent containing those |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-380547 | 2005-12-29 | ||
JP2005380547 | 2005-12-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007074868A1 true WO2007074868A1 (ja) | 2007-07-05 |
Family
ID=38218090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/326061 WO2007074868A1 (ja) | 2005-12-29 | 2006-12-27 | 新規なアリールアミジン誘導体およびその塩ならびにそれらを含有する抗真菌剤 |
Country Status (21)
Country | Link |
---|---|
US (1) | US8536343B2 (ja) |
EP (1) | EP1967190B1 (ja) |
JP (1) | JP5038155B2 (ja) |
KR (1) | KR101359363B1 (ja) |
CN (1) | CN101351204B (ja) |
AU (1) | AU2006330408B2 (ja) |
BR (1) | BRPI0620732A2 (ja) |
CA (1) | CA2634846C (ja) |
CY (1) | CY1110857T1 (ja) |
DE (1) | DE602006016010D1 (ja) |
DK (1) | DK1967190T3 (ja) |
ES (1) | ES2349146T3 (ja) |
IL (1) | IL192380A0 (ja) |
NO (1) | NO20082698L (ja) |
NZ (1) | NZ569317A (ja) |
PL (1) | PL1967190T3 (ja) |
PT (1) | PT1967190E (ja) |
RU (1) | RU2415839C2 (ja) |
SI (1) | SI1967190T1 (ja) |
WO (1) | WO2007074868A1 (ja) |
ZA (1) | ZA200805604B (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008044562A1 (fr) * | 2006-10-06 | 2008-04-17 | Toyama Chemical Co., Ltd. | Composition pharmaceutique contenant un dérivé de phénylamidine et procédé d'utilisation de la composition pharmaceutique combinée à un agent antifongique |
WO2009005077A1 (ja) | 2007-07-04 | 2009-01-08 | Toyama Chemical Co., Ltd. | 4-{3-[4-(3-{4-[アミノ(ブトキシカルボニルイミノ)メチル]フェノキシ}プロピル)-1-ピペリジニル]プロポキシ}-n’-(ブトキシカルボニル)ベンズアミジンの新規な結晶 |
WO2015087857A1 (ja) * | 2013-12-10 | 2015-06-18 | 日本曹達株式会社 | アリールアミジン化合物および殺菌剤 |
JP2015534551A (ja) * | 2012-09-14 | 2015-12-03 | スパーナス ファーマシューティカルズ インコーポレイテッド | モリンドン及びその塩の製造方法 |
WO2016047550A1 (ja) * | 2014-09-24 | 2016-03-31 | 日本曹達株式会社 | アリールアミジン化合物を含有する農園芸用殺菌剤 |
JPWO2016195077A1 (ja) * | 2015-06-03 | 2018-02-01 | 日本曹達株式会社 | グアニジン化合物および殺菌剤 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08231515A (ja) * | 1994-12-01 | 1996-09-10 | Toyama Chem Co Ltd | 新規な2,3−ジケトピペラジン誘導体またはその塩 |
US20030130265A1 (en) * | 2001-09-08 | 2003-07-10 | Boehringer Ingelheim Pharma Kg | Benzimidazole derivatives, a process for their manufacture and use as a medicine |
WO2003074476A1 (fr) * | 2002-03-06 | 2003-09-12 | Toyama Chemical Co., Ltd. | Nouveau derive d'arylamidine ou sel de celui-ci |
JP2005097298A (ja) * | 2003-09-05 | 2005-04-14 | Toyama Chem Co Ltd | 新規なアリールアミジン誘導体またはその塩 |
WO2006003881A1 (ja) * | 2004-06-30 | 2006-01-12 | Toyama Chemical Co., Ltd. | 新規なアリールアミジン誘導体およびその塩ならびにそれらを含有する抗真菌剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU691361B2 (en) | 1994-12-01 | 1998-05-14 | Toyama Chemical Co. Ltd. | Novel 2,3-diketopiperazine derivative or salt thereof |
US6319944B1 (en) | 1999-05-10 | 2001-11-20 | Merck & Co., Inc. | Aryl amidines, compositions containing such compounds and methods of use |
ES2282127T3 (es) * | 1999-07-08 | 2007-10-16 | University Of North Carolina At Chapel Hill | Nuevos profarmacos para amidinas anticrobianas. |
BRPI0607910A2 (pt) | 2005-04-07 | 2010-03-23 | Toyama Chemical Co Ltd | composiÇço farmacÊutica para tratar infecÇÕes féngicas, e, mÉtodo de uso de um derivado de arilamidina ou um sal do mesmo |
-
2006
- 2006-12-27 WO PCT/JP2006/326061 patent/WO2007074868A1/ja active Application Filing
- 2006-12-27 DK DK06843443.0T patent/DK1967190T3/da active
- 2006-12-27 US US12/159,527 patent/US8536343B2/en not_active Expired - Fee Related
- 2006-12-27 DE DE602006016010T patent/DE602006016010D1/de active Active
- 2006-12-27 CN CN2006800497554A patent/CN101351204B/zh not_active Expired - Fee Related
- 2006-12-27 JP JP2007552006A patent/JP5038155B2/ja not_active Expired - Fee Related
- 2006-12-27 BR BRPI0620732-4A patent/BRPI0620732A2/pt not_active IP Right Cessation
- 2006-12-27 AU AU2006330408A patent/AU2006330408B2/en not_active Ceased
- 2006-12-27 EP EP06843443A patent/EP1967190B1/en not_active Not-in-force
- 2006-12-27 SI SI200630810T patent/SI1967190T1/sl unknown
- 2006-12-27 NZ NZ569317A patent/NZ569317A/en unknown
- 2006-12-27 RU RU2008131044/04A patent/RU2415839C2/ru not_active IP Right Cessation
- 2006-12-27 PT PT06843443T patent/PT1967190E/pt unknown
- 2006-12-27 ZA ZA200805604A patent/ZA200805604B/xx unknown
- 2006-12-27 CA CA2634846A patent/CA2634846C/en not_active Expired - Fee Related
- 2006-12-27 KR KR1020087018282A patent/KR101359363B1/ko not_active IP Right Cessation
- 2006-12-27 ES ES06843443T patent/ES2349146T3/es active Active
- 2006-12-27 PL PL06843443T patent/PL1967190T3/pl unknown
-
2008
- 2008-06-12 NO NO20082698A patent/NO20082698L/no not_active Application Discontinuation
- 2008-06-22 IL IL192380A patent/IL192380A0/en not_active IP Right Cessation
-
2010
- 2010-10-27 CY CY20101100969T patent/CY1110857T1/el unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08231515A (ja) * | 1994-12-01 | 1996-09-10 | Toyama Chem Co Ltd | 新規な2,3−ジケトピペラジン誘導体またはその塩 |
US20030130265A1 (en) * | 2001-09-08 | 2003-07-10 | Boehringer Ingelheim Pharma Kg | Benzimidazole derivatives, a process for their manufacture and use as a medicine |
WO2003074476A1 (fr) * | 2002-03-06 | 2003-09-12 | Toyama Chemical Co., Ltd. | Nouveau derive d'arylamidine ou sel de celui-ci |
JP2005097298A (ja) * | 2003-09-05 | 2005-04-14 | Toyama Chem Co Ltd | 新規なアリールアミジン誘導体またはその塩 |
WO2006003881A1 (ja) * | 2004-06-30 | 2006-01-12 | Toyama Chemical Co., Ltd. | 新規なアリールアミジン誘導体およびその塩ならびにそれらを含有する抗真菌剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1967190A4 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008044562A1 (fr) * | 2006-10-06 | 2008-04-17 | Toyama Chemical Co., Ltd. | Composition pharmaceutique contenant un dérivé de phénylamidine et procédé d'utilisation de la composition pharmaceutique combinée à un agent antifongique |
EP2070536A4 (en) * | 2006-10-06 | 2010-02-10 | Toyama Chemical Co Ltd | PHARMACEUTICAL COMPOSITION CONTAINING PHENYLAMIDINE DERIVATIVE AND METHOD OF USING THE PHARMACEUTICAL COMPOSITION COMBINED WITH AN ANTIFUNGAL AGENT |
US8173157B2 (en) | 2006-10-06 | 2012-05-08 | Toyama Chemical Co., Ltd. | Pharmaceutical composition comprising phenylamidine derivative and method of using the pharmaceutical composition in combination with antifungal agent |
WO2009005077A1 (ja) | 2007-07-04 | 2009-01-08 | Toyama Chemical Co., Ltd. | 4-{3-[4-(3-{4-[アミノ(ブトキシカルボニルイミノ)メチル]フェノキシ}プロピル)-1-ピペリジニル]プロポキシ}-n’-(ブトキシカルボニル)ベンズアミジンの新規な結晶 |
US8158800B2 (en) | 2007-07-04 | 2012-04-17 | Toyama Chemical Co., Ltd. | 4-{3-[4-(3-{4-[amino (butoxycarbonylimino) methyl] phenoxy} propyl)-1-piperidinyl] propoxy}-N'-(butoxycarbonyl) benzamidine crystals |
TWI395735B (zh) * | 2007-07-04 | 2013-05-11 | Toyama Chemical Co Ltd | 4-{3-〔4-(3-{4-〔胺基(丁氧基羰基亞胺基)甲基〕苯氧基}丙基)-1-哌啶基〕丙氧基}-n’-(丁氧基羰基)苄脒之新穎結晶 |
JP5261386B2 (ja) * | 2007-07-04 | 2013-08-14 | 富山化学工業株式会社 | 4−{3−[4−(3−{4−[アミノ(ブトキシカルボニルイミノ)メチル]フェノキシ}プロピル)−1−ピペリジニル]プロポキシ}−n’−(ブトキシカルボニル)ベンズアミジンの新規な結晶 |
JP2015534551A (ja) * | 2012-09-14 | 2015-12-03 | スパーナス ファーマシューティカルズ インコーポレイテッド | モリンドン及びその塩の製造方法 |
US9562011B2 (en) | 2012-09-14 | 2017-02-07 | Supernus Pharmaceuticals, Inc. | Methods of producing molindone and its salts |
US9802893B2 (en) | 2012-09-14 | 2017-10-31 | Supernus Pharmaceuticals, Inc. | Methods of producing molindone and its salts |
US10081595B2 (en) | 2012-09-14 | 2018-09-25 | Supernus Pharmaceuticals, Inc. | Methods of producing molindone and its salts |
US10676432B2 (en) | 2012-09-14 | 2020-06-09 | Supernus Pharmaceuticals, Inc. | Methods of producing molindone and its salts |
US11117862B2 (en) | 2012-09-14 | 2021-09-14 | Supernus Pharmaceuticals, Inc. | Methods of producing molindone and its salts |
WO2015087857A1 (ja) * | 2013-12-10 | 2015-06-18 | 日本曹達株式会社 | アリールアミジン化合物および殺菌剤 |
JPWO2015087857A1 (ja) * | 2013-12-10 | 2017-03-16 | 日本曹達株式会社 | アリールアミジン化合物および殺菌剤 |
WO2016047550A1 (ja) * | 2014-09-24 | 2016-03-31 | 日本曹達株式会社 | アリールアミジン化合物を含有する農園芸用殺菌剤 |
JPWO2016195077A1 (ja) * | 2015-06-03 | 2018-02-01 | 日本曹達株式会社 | グアニジン化合物および殺菌剤 |
US10111437B2 (en) | 2015-06-03 | 2018-10-30 | Nippon Soda Co., Ltd. | Substituted guanidines as fungicides |
Also Published As
Publication number | Publication date |
---|---|
IL192380A0 (en) | 2008-12-29 |
BRPI0620732A2 (pt) | 2011-11-22 |
KR20080080227A (ko) | 2008-09-02 |
ES2349146T3 (es) | 2010-12-28 |
EP1967190A1 (en) | 2008-09-10 |
PT1967190E (pt) | 2010-10-14 |
CY1110857T1 (el) | 2015-06-10 |
EP1967190A4 (en) | 2009-08-26 |
AU2006330408A1 (en) | 2007-07-05 |
AU2006330408B2 (en) | 2011-10-13 |
RU2415839C2 (ru) | 2011-04-10 |
NZ569317A (en) | 2010-08-27 |
US20100016602A1 (en) | 2010-01-21 |
SI1967190T1 (sl) | 2010-12-31 |
CN101351204B (zh) | 2011-01-12 |
RU2008131044A (ru) | 2010-02-10 |
US8536343B2 (en) | 2013-09-17 |
NO20082698L (no) | 2008-09-05 |
PL1967190T3 (pl) | 2011-01-31 |
JPWO2007074868A1 (ja) | 2009-06-04 |
JP5038155B2 (ja) | 2012-10-03 |
ZA200805604B (en) | 2009-12-30 |
EP1967190B1 (en) | 2010-08-04 |
DK1967190T3 (da) | 2010-11-22 |
CN101351204A (zh) | 2009-01-21 |
CA2634846A1 (en) | 2007-07-05 |
DE602006016010D1 (de) | 2010-09-16 |
KR101359363B1 (ko) | 2014-02-07 |
CA2634846C (en) | 2013-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fylaktakidou et al. | Recent developments in the chemistry and in the biological applications of amidoximes | |
JP4885722B2 (ja) | 新規なアリールアミジン誘導体およびその塩ならびにそれらを含有する抗真菌剤 | |
CA1340962C (en) | Arylhydrazones | |
WO2007074868A1 (ja) | 新規なアリールアミジン誘導体およびその塩ならびにそれらを含有する抗真菌剤 | |
TW201103893A (en) | New compounds | |
CN106892878B (zh) | 噻唑类衍生物及其在抑制二氢乳清酸脱氢酶中的应用 | |
JP3539926B2 (ja) | 抗ウイルス性ピリミジンジオン誘導体及びそれらの製造方法 | |
WO2006011499A1 (ja) | 新規なアリールアミジン誘導体およびその塩ならびにそれらを含有する抗真菌剤 | |
AU2017405244C9 (en) | Novel pyrrolopyridine derivative, method for producing same, and use thereof | |
US20100099732A1 (en) | Medicaments useful as potassium channel modulators | |
JPS61130280A (ja) | ピペリジン誘導体 | |
JPH07188197A (ja) | オキサゾール誘導体 | |
WO2019042443A1 (zh) | 一类具有降解酪氨酸蛋白激酶jak3活性的化合物 | |
CN110612289B (zh) | 氘代的苯并咪唑化合物和其医药用途 | |
US6818653B1 (en) | 6,7-Disubstituted -5,8-quinolinedione derivatives as an antifungal agent | |
Al Abdullah | Synthesis and biological testing of new 1-adamantyl derivatives | |
WO2017181948A1 (zh) | 取代的恶唑烷酮化合物及其应用 | |
MX2008008395A (es) | Nuevo derivado de arilamidina, sal del mismo y agente antifungico que los contiene. | |
JENA et al. | Synthesis, Biological Evaluation, Molecular Modeling, and Docking Studies of Ciprofloxacin Derivatives | |
WO2023091565A1 (en) | Nsd2-targeted chemical degraders and compositions and methods of use thereof | |
WO2016095878A1 (en) | Substituted derivative of oxyphosphorus acids, its use and pharmaceutical preparation containing it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680049755.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2007552006 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006843443 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2456/KOLNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006330408 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 569317 Country of ref document: NZ Ref document number: 2634846 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2008/008395 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12159527 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006330408 Country of ref document: AU Date of ref document: 20061227 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087018282 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008131044 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0620732 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080627 |